November 23, 2022

Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference

ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside chat at 9:30 a.m. EST, as well as one-on-one… Read More
learn more
November 17, 2022

Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting

Health economics and outcomes research showed post-Stupp therapeutic developments, including TTFields, significantly increase overall survival in a large commercially insured population The largest safety dataset to date of more than 23,000 patients reinforced that TTFields therapy is well-tolerated in patients with high-grade gliomas ROOT, Switzerland–(BUSINESS WIRE)–Novocure… Read More
learn more
November 15, 2022

Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada

Novocure chose Montreal because of its innovative culture, world-class universities and hospitals, access to top talent and quality of life ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. Novocure is a global… Read More
learn more
November 11, 2022

Novocure Secures CE Mark for New Array

New arrays are lighter, thinner and more flexible than current commercial arrays and have the potential to optimize Tumor Treating Fields dose ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor… Read More
learn more
October 27, 2022

Novocure Reports Third Quarter 2022 Financial Results

Quarterly net revenues of $131 million with $52 million invested in research & development initiatives Entering a transformational period with multiple pivotal trial readouts anticipated in coming quarters ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022. Novocure is a… Read More
learn more
October 21, 2022

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

Highlights include an analysis of predictive biomarkers for overall survival and progression free survival in newly diagnosed glioblastoma patients Pre-clinical research shows the potential for improved tumor control when Tumor Treating Fields are used with PULSAR in glioblastoma, PARP inhibitors in ovarian cancer and PI3K inhibitors in non-small… Read More
learn more
October 20, 2022

Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology

A fast-growing body of research, both in vitro and in vivo, is converging to demonstrate the multiple inhibitory effects of Tumor Treating Fields on cancer growth The review article summarizes the known mechanisms of action of Tumor Treating Fields that have been reported by in vitro and in… Read More
learn more
October 20, 2022

Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy

Campaign urges healthcare providers to harness the versatile power of electric fields to outsmart solid tumors ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an emerging… Read More
learn more
October 3, 2022

Novocure to Report Third Quarter 2022 Financial Results

ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and nine… Read More
learn more
September 21, 2022

Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business

Frank Leonard is appointed President, CNS Cancers U.S.  ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve coordination across Novocure’s U.S. CNS business, and is intended to renew… Read More
learn more